Henig spent 2008 through 2014 at Gilead Sciences where she held roles with increasing responsibility, including building and leading a global medical affairs organization, strategic development of clinical trials Phase 2-4, regulatory strategy, corporate development, leadership of key alliances and commercial strategy. Henig was Chief Medical Officer at ProQR Therapeutics where she brought two unique RNA oligonucleotides through early clinical trials in rare diseases.

Henig built and led the clinical team and was responsible for all development activities including clinical and non-clinical science, clinical operations, regulatory, project management, and medical affairs. She currently serves on the Board of Avidity Biosciences and most recently served as Chief Medical Officer of Breath Therapeutics, which was acquired by Zambon SpA in 2019. is an accomplished leader whose career spans clinical practice, academic medicine, translational science, clinical development, medical and regulatory affairs. from Stanford University, where during his undergraduate years he competed on the varsity track team. in International Relations and his M.B.A. He began his career on Capitol Hill and later in the Clinton Administration, as a Congressional Affairs Specialist for the U.S. Prior to his CEO roles, John also worked with Idealab Silicon Valley and as a management consultant with William Kent International, advising clients on international acquisition opportunities and market entry strategies.

From 2003 to 2008 John served as CEO of specialty shipping company Aero Logistics, which he and a business partner acquired using a specialty investment company they founded in 2001. Prior to co-founding Kezar, between 20 John co-founded and was CEO of HealthCPA, a provider of patient advocacy and insurance navigation services. John Fowler is our Co-Founder, Chief Executive Officer, and a member of the board of directors, bringing over 20 years of executive leadership experience to the company.

Operation Einstein by Mark A. Cooper